50% INSULIN LISPRO PROTAMINE SUSPENSION AND
50% INSULIN LISPRO INJECTION
UNITS PER ML (U-100)
Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)] is a mixture of insulin lispro solution, a rapid–acting blood glucose–lowering agent and insulin lispro protamine suspension, an intermediate–acting blood glucose–lowering agent.
Humalog Mix50/50, a mixture of 50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin), is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Based on cross–study comparisons of the pharmacodynamics of Humalog Mix50/50 and Humulin 50/50, it is likely that Humalog Mix50/50 has a more rapid onset of glucose–lowering activity compared with Humulin 50/50 while having a similar duration of action. This profile is achieved by combining the rapid onset of Humalog with the intermediate action of insulin lispro protamine suspension.
Published Studies Related to Humalog Mix50 / 50 (Insulin Lispro Subcutaneous)
Comparative pharmacokinetics and insulin action for three rapid-acting insulin
analogs injected subcutaneously with and without hyaluronidase. 
CONCLUSIONS: Coinjection of rHuPH20 with rapid-acting analogs accelerated insulin
Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial. [2011.06]
BACKGROUND: In a previous pilot study comparing insulin glulisine (GLU) with insulin aspart (ASP) administered by continuous subcutaneous insulin infusion (CSII), GLU-treated patients did show a trend toward fewer catheter occlusions compared with ASP-treated patients. Here we performed a randomized open-label, three-way crossover, controlled multicenter study comparing GLU with ASP and insulin lispro (LIS)... CONCLUSIONS: GLU was not superior to ASP and LIS with no significant difference seen among GLU, ASP, and LIS in CSII use with respect to unexplained hyperglycemia and/or perceived catheter set occlusion. GLU was associated with a higher frequency of symptomatic hypoglycemia, possibly because of slight overdosing, as previous trials suggested lower insulin requirements when GLU is initiated in type 1 diabetes.
Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes. [2011.04]
CONCLUSIONS: PPG with RHI administered ID via microneedle was improved versus SC delivery when dosed 17 min premeal. ID RHI provided similar control of PPG as SC IL immediately premeal. Further studies of ID insulin delivery via steel microneedles are warranted.
Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. [2010.12]
CONCLUSIONS: Absorption and hypoglycemic action of increasing dosages of lispro are critically delayed in obese subjects with type 2 diabetes.
Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. [2010.08]
Intensive insulin therapy for diabetic patients has been demonstrated as an appropriate treatment... Insulin analogs Glulisine and Lispro were proved to have equivalent pharmacokinetic and pharmacodynamic parameters when administered to healthy Chinese adults, but with Glulisine showing greater AUC(0-1h) after injection.
Clinical Trials Related to Humalog Mix50 / 50 (Insulin Lispro Subcutaneous)
Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus [Completed]
Humalog and Humulin-R (recombinant human insulin) are Food and Drug Administration (FDA)
approved medications for the treatment of diabetes mellitus. Recombinant human hyaluronidase
PH20 (rHuPH20) is approved by the FDA for use as an aid in the absorption and dispersion of
other injectable drugs. In this study, rHuPH20 will be co-administered with both Humalog and
Humulin-R in order to determine if it improves the absorption of these insulins to more
closely mimic the body's natural increase in insulin in response to a meal.
Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics [Withdrawn]
This is a randomized, parallel group comparison of the immunogenicity safety of Wockhardt's
Insulin analogue Lispro and lispro Mix with Eli Lilly's Insulin analogue HumalogŪ and
HumalogŪ Mix in patients with Type 1 Diabetes Mellitus
HumalogŪ Mix50/50(tm) as a Treatment for Gestational Diabetes [Completed]
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use [Completed]
This is a 6-sequence, 3-period (8 weeks each), 3-arm, 24-week crossover study. The purpose
of this study is to provide information on the use of insulin lispro in insulin pumps
(Continuous Subcutaneous Insulin Infusion [CSII]) compared to insulin aspart over 6 days of
pump reservoir in-use. The study will also compare the in-use characteristics of insulin
lispro infused at 6 days with insulin lispro infused at 2 days.
A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants [Completed]
BC106 is a molecule that when injected with insulin lispro may change the speed of
absorption of insulin lispro. The purpose of this study will be to evaluate the safety of
BC106 insulin lispro and any side effects that might be associated with it, blood levels of
insulin lispro after injection under the skin and how BC106 insulin lispro affects blood
sugar after injection under the skin. There is a minimum 7 day washout between single doses.